<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312908</url>
  </required_header>
  <id_info>
    <org_study_id>14172EuiYakAn178</org_study_id>
    <nct_id>NCT02312908</nct_id>
  </id_info>
  <brief_title>Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism</brief_title>
  <official_title>Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism: a Prospective, Randomized, Double-blind and Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Food and Drug Safety, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether clonazepam is effective and safe in the
      treatment of rapid eye movement behavior disorder (RBD) of patients with Parkinson's disease
      (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RBD is one of the representative non-motor symptoms of PD and other synucleinopathies.
      Patients with RBD show dream-enacting behaviors such as punching, kicking, singing,
      screaming, or somnambulism. These can interfere in sleep quality and increase the risk of
      falling down from the bed and physical injuries of both the patient and sleep partner.
      Therefore, qualities of life of the patient and sleep partner are negatively influenced by
      presence of RBD.

      Clonazepam has been used for treatment of choice of RBD. It decreased RBD symptoms completely
      in 55-79% and partially in 11-32% of patients. However, these results are based on open-label
      or descriptive studies. There has been no randomized placebo controlled study that evaluated
      the efficacy and safety of clonazepam for treating RBD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression-Improvement scale (CGI-I)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
    <description>Clinician assessed rating scale of clinical improvement or worsening relative to a baseline state, scored as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity scale (CGI-S)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson Disease Sleep Scale (PDSS)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>Four weeks (plus or minus 3 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>REM Sleep Behavior Disorder</condition>
  <arm_group>
    <arm_group_label>Clonazepam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clonazepam 0.5 mg 1 Tablet by mouth, 1/day before sleeping for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 Tablet by mouth, 1/day before sleeping for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonazepam</intervention_name>
    <description>For experimental treatment of RBD</description>
    <arm_group_label>Clonazepam</arm_group_label>
    <other_name>Rivotril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill manufactured to mask clonazepam 0.5mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet of Rivotril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was enrolled voluntarily and understood the contents of this clinical trial

          -  Subject was diagnosed as Parkinson disease (PD) or Parkinson's syndrome

          -  Hoehn and Yahr (H&amp;Y) stage 1, 2, or 3

          -  Existence of caregivers who can provide a information about symptoms of rapid eye
             movement sleep disorder (RBD) of the participant

          -  Existence of RBD by answering &quot;yes&quot; to the question (RBD-1Q): &quot;Have you ever been
             told, or suspected yourself, that you seem to 'act out your dreams' while asleep (for
             example, punching, flailing your arms in the air, making running movements, etc.)?&quot;

        Exclusion Criteria:

          -  Existence of cognitive decline hard to participate in the clinical trial

          -  Subject has confusion or visual hallucination in daytime

          -  Diagnosed as obstructive sleep apnea or severe snoring

          -  Previous clonazepam treatment within 4 weeks

          -  Current treatment with benzodiazepines at bedtime

          -  Alcoholics or drug abuser

          -  Lactating, pregnant, or possible pregnant

          -  Hypersensitivity to clonazepam or benzodiazepines

          -  Prior participation to other clinical trials within 3 months

          -  Presence of severe comorbidities or a cancer

          -  Existence of illness or problems which makes difficult to be enrolled to this trial
             judged by clinicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beom Seok Jeon, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Arnulf I. REM sleep behavior disorder: motor manifestations and pathophysiology. Mov Disord. 2012 May;27(6):677-89. doi: 10.1002/mds.24957. Epub 2012 Mar 22. Review.</citation>
    <PMID>22447623</PMID>
  </reference>
  <reference>
    <citation>Sixel-DÃ¶ring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology. 2011 Sep 13;77(11):1048-54. doi: 10.1212/WNL.0b013e31822e560e. Epub 2011 Aug 10.</citation>
    <PMID>21832215</PMID>
  </reference>
  <reference>
    <citation>Postuma RB, Bertrand JA, Montplaisir J, Desjardins C, Vendette M, Rios Romenets S, Panisset M, Gagnon JF. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study. Mov Disord. 2012 May;27(6):720-6. doi: 10.1002/mds.24939. Epub 2012 Feb 9.</citation>
    <PMID>22322798</PMID>
  </reference>
  <reference>
    <citation>Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006 Sep 12;67(5):742-7.</citation>
    <PMID>16966533</PMID>
  </reference>
  <reference>
    <citation>Schenck CH, Hurwitz TD, Mahowald MW. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res. 1993 Dec;2(4):224-231.</citation>
    <PMID>10607098</PMID>
  </reference>
  <reference>
    <citation>Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000 Feb;123 ( Pt 2):331-9.</citation>
    <PMID>10648440</PMID>
  </reference>
  <reference>
    <citation>Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011 Dec 15;7(6):639-644A. doi: 10.5664/jcsm.1470.</citation>
    <PMID>22171203</PMID>
  </reference>
  <reference>
    <citation>Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, Karippot A, Ramar K, Kristo DA, Morgenthaler TI; Standards of Practice Committee; American Academy of Sleep Medicine. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010 Feb 15;6(1):85-95. Erratum in: J Clin Sleep Med. 2010 Apr 15;6(2):table of contents.</citation>
    <PMID>20191945</PMID>
  </reference>
  <reference>
    <citation>De Cock VC, Vidailhet M, Arnulf I. Sleep disturbances in patients with parkinsonism. Nat Clin Pract Neurol. 2008 May;4(5):254-66. doi: 10.1038/ncpneuro0775. Epub 2008 Apr 8. Review.</citation>
    <PMID>18398415</PMID>
  </reference>
  <reference>
    <citation>Postuma RB, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y, Oertel W, Ju YE, Puligheddu M, Jennum P, Pelletier A, Wolfson C, Leu-Semenescu S, Frauscher B, Miyamoto M, Cochen De Cock V, Unger MM, Stiasny-Kolster K, Fantini ML, Montplaisir JY. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012 Jun;27(7):913-6. doi: 10.1002/mds.25037. Epub 2012 May 30.</citation>
    <PMID>22729987</PMID>
  </reference>
  <reference>
    <citation>Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010 Dec;19(4):591-6. doi: 10.1111/j.1365-2869.2010.00848.x.</citation>
    <PMID>20561180</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>BS Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>REM Sleep Behavior Disorder</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>Placebos</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Double-Blind Method</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

